Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 4/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.52 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091625 | 0.87 | NPY5R (0.57) | ACP1IGF1R | |
| SCHEMBL20680287 | 0.86 | ACP1 (0.60) | ACP1ABCG2EGFRSOS1PTK6 | |
| SCHEMBL6071699 | 0.81 | FADS1 (0.68) | ACP1ABCG2EGFRPTK6 | |
| SCHEMBL11813883 | 0.78 | IGF1R (0.50) | ACP1ABCG2IGF1R | |
| SCHEMBL29230206 | 0.76 | SOS1 (0.59) | ACP1ABCG2EGFRSOS1RXFP1 | |
| SCHEMBL30944934 | 0.76 | SOS1 (0.59) | ACP1ABCG2EGFRSOS1RXFP1 | |
| SCHEMBL8297458 | 0.76 | ACP1 (0.53) | ACP1ABCG2EGFRSOS1PTK6 | |
| SCHEMBL6234079 | 0.76 | SLC2A1 (0.50) | ACP1ABCG2EGFRSOS1RXFP1 | |
| SCHEMBL28219993 | 0.75 | KMT2A (0.51) | ACP1ABCG2IGF1R | |
| SCHEMBL6088381 | 0.75 | SMN1; SMN2 (0.52) | ACP1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | ACP1 465/4885ABCG2 2427/4885EGFR 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.